Welcome to our dedicated page for CareDx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CareDx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CareDx's regulatory disclosures and financial reporting.
State Street Corporation reported beneficial ownership of CareDx, Inc. common stock on a Schedule 13G. It reported holding 2,468,858 shares of common stock, representing 4.8% of the class.
All voting and dispositive authority is shared through affiliated investment adviser entities, with 2,351,509 shares subject to shared voting power and 2,468,858 shares subject to shared dispositive power. State Street has no sole voting or dispositive power. The filing classifies the position as ownership of 5 percent or less of the class.
CareDx, Inc. director George Bickerstaff sold 20,000 shares of Common Stock on August 5, 2026 in a non-derivative sale transaction. The shares were sold at a weighted average price of $46.285 per share, across trades from $46.14 to $47.06, leaving him directly holding 134,061 shares.
CareDx, Inc. director Christine Cournoyer sold 16,000 shares of common stock on 2026-08-04 in open-market transactions under a Rule 10b5-1 trading plan. The weighted average sale price was $46.9358 per share, within a $46.25–$47.2250 range, leaving her with 42,943 shares held directly.
CareDx, Inc. reports that Secretary and General Counsel Jeffrey Adam Novack sold a total of 2,688 shares of common stock on August 5, 2026, in open-market or private transactions pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025. The sales comprised 2,188 shares at a weighted average price of $46.1492 (range $45.49–$46.45) and 500 shares at $46.75 (range $46.59–$46.94).
CareDx, Inc. director Michael Goldberg reported selling 44,700 shares of Common Stock on August 4, 2026 at an average price of $47.0581 per share. After the sale he holds 61,738 shares directly and 91,045 shares indirectly through the Cavallo Trust, where he and his spouse are trustees.
A Form 144 notice for CDNA reports a proposed sale of up to 46,963 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,178,945.34 as of 08/05/2026. The planned sales relate to restricted stock grants of 3,268 and 10,570 shares and a stock option exercise covering 33,125 shares. The notice also lists that Peter Maag sold 75,653 shares of common stock for $3,576,851.19 on 08/04/2026 within the prior three months.
CareDx, Inc. reported that Secretary and General Counsel Jeffrey Adam Novack had 2,872 shares of common stock withheld on August 1, 2026 at $47.85 per share to satisfy tax withholding obligations related to vesting restricted stock units. After this disposition, he directly holds 108,763 shares of CareDx common stock.
CareDx, Inc. filed a notice relating to a proposed sale of its common stock through Goldman Sachs & Co. LLC. The filing indicates a planned sale of 16,000 shares, with an aggregate market value of $753,440, on or about 08/04/2026 on NASD.
The securities to be sold were acquired from the issuer as compensation in the form of Restricted Stock Units, including awards dated 06/14/2025 for 10,570 shares and 03/07/2025 for 5,430 shares. The issuer’s common shares outstanding are listed as 51,734,223.